Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Developments in surgery for early stage lung cancer

Bookmark and Share

BGICC 2023

19 - 20 Jan 2023
Published: 1 Feb 2023
Views: 17
Rating:
Save
Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland

Prof Walter Weder speaks to ecancer at BGICC 2023 about developments in surgery for early stage lung cancer.

He outlines two studies from the past few years that have significantly impacted surgical approaches.

Prof Weder summarises that the results showed the overall survival was 3% better for lung cancer patients who received a segmentectomy versus a lobectomy.

Related Videos

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free...
Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable...
Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023
Surgical technique remains the most important factor associated with recovery...
Dr Rafael Sanchez-Salas - McGill University Health Center, Montreal, Canada
Surgical technique remains the most important factor associated with recovery of urinary continence after radical prostatectomy ( Dr Rafael Sanchez-Salas - McGill University Health Center, Montreal, Canada )
16 Mar 2023
IORT at the Asian Hospital and Medical Center
Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines
IORT at the Asian Hospital and Medical Center ( Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines )
9 Mar 2023
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation...
Dr Jayant Vaidya - University College London, London, UK
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival ( Dr Jayant Vaidya - University College London, London, UK )
9 Mar 2023
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast...
Dr Jayant Vaidya - University College London, London, UK
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )
9 Mar 2023
Metastatic bone disease: Importance of bone-targeted agents
Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert...
Metastatic bone disease: Importance of bone-targeted agents ( Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert Coleman - The University of Sheffield, Sheffield, UK )
23 Feb 2023
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...
Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023
The role of multidisciplinary tumour board in managing stage 3 lung cancer
Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland
The role of multidisciplinary tumour board in managing stage 3 lung cancer ( Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland )
1 Feb 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation